Donate For Public and Patients Store Search

Go to AAD Home

AAD Virtual Meeting Experience (VMX)

Banner for AAD VMX 2020

Introducing AAD VMX

Earn over 32.5 AMA PRA CME Credit™ for participating!

AAD VMX includes 14 robust sessions covering topics such as therapeutics, cosmetics, psoriasis, hair disorders, and more – plus 4 late breaking research sessions.

Stop by the virtual exhibit hall and view over 900 ePosters.

See the VMX program guide (PDF download).

All of the sessions and other features available on-demand until Dec. 31, 2020. Purchasing is now closed.

AAD VMX is now open!

If you're already registered click the Go to VMX button.

Go to VMX

AAD VMX is subject to standard AAD return policy.

VMX registrant data privacy policy

Looking for help in navigating the AAD VMX? Access our FAQS (PDF download).

Explore AAD VMX

  • Scientific sessions
  • Late-breaking research
  • Plenary
  • Exhibits, networking, and more!
  • Residents' activities
  • VMX award winners
  • Meeting News
  • All sessions will be available on-demand beginning Friday, June 12 at 2 p.m. CT.

    Live events, including Q&A with the speakers, will take place Friday, June 12 – Sunday, June 14. All content will be available on-demand through December 31, 2020.

    This activity is approved for 32.5 AMA PRA CME Credit™.

    Scientific sessions

    • Micrographic Dermatologic Surgery (MDS) Subspecialty Certification Exam Prep Course: This will be a question and explanation based, session covering the subjects in the MDS Exam Review Guide to assist in preparations for the American Board of Dermatology’s MDS Subspecialty Certification Exam.

      • Ian A. Maher, MD, FAAD: Flaps

      • Addison Michael Demer, MD, FAAD: Wound healing and perioperative care

      • Martha Laurin Council, MD, FAAD: Rare tumors and guidelines

      • Lori Fiessinger, MD, FAAD: Genetics and adjuvant therapy for skin cancer

      • David R. Carr, MD, FAAD: Radiation, complex tumors, and laboratory

    • Therapeutic Hotline: This session will review new and emerging therapeutics for patients with psoriasis, dyspigmentation, and hair diseases. The newest and what's hot in dermatology ranging from medical to cosmetic to surgical dermatology will be addressed.

      • Hema A. Sundaram, MD, FAAD: What's New in Aesthetic Therapeutics

      • Seemal R. Desai, MD, FAAD: What's New in Vitiligo

      • Jerry Shapiro, MD, FAAD: What's New in Hair Loss

      • Mark Lebwohl, MD, FAAD: What's New In Psoriasis

    • JAK Inhibitors: A New Frontier in Dermatology: The recent emergence of Janus kinase (JAK) inhibitors has led to new therapeutic options in dermatology. The application of JAK inhibitors to common dermatologic diseases, with significant unmet medical need, will be presented, including the results of clinical trials and case series. Safety will be discussed. The audience for this session will be dermatologists who care for patients with vitiligo, atopic dermatitis, psoriasis, granuloma annulare and sarcoidosis, , in addition to other conditions.

      • Eric Lawrence Simpson, MD, FAAD: Atopic Dermatitis

      • Jeffrey M. Sobell, MD, FAAD: Psoriasis

      • David Rosmarin, MD, FAAD: Vitiligo

      • William Damsky, MD, PhD: Sarcoidosis, Granuloma Annulare

    • Therapeutic and Diagnostic Pearls: This session will highlight important diagnostic and therapeutic pearls and is directed towards both novice and experienced clinicians. Information discussed will be based on both peer-reviewed literature and the result of personal experience.

      • Paradi Mirmirani, MD, FAAD: Hair

      • Esteban Fernandez Faith, MD, FAAD: Pediatric Pearls

      • Victoria P. Werth, MD, FAAD: Autoimmune connective tissue and bullous disease

    • What's New in Dermatology: This session will review new developments in dermatologic surgery, cosmetic dermatology, pediatric dermatology, and medical dermatology. Specific sessions will present new information from acne, rosacea, hidradenitis, and psoriasis, and there will be a session devoted to systemic dermatologic therapy.

      • Terrence A. Cronin, Jr., MD, FAAD: What's New in Dermatologic Surgery & Cosmetic Dermatology

      • Mark Lebwohl, MD, FAAD: What's New in Systemic Dermatologic Therapy

      • Bruce Elliot Strober, MD, PhD, FAAD: What's New in Psoriasis

      • Kari Martin, MD, FAAD: Pediatric Contact Dermatitis

    • What's New in Dermatopathology: This symposium provides information regarding advances in key areas of dermatopathology. Histopathologic findings of COVID-19, neoplastic lesions, inflammatory dermatitis, recent acceptable use criteria, molecular techniques, translational research, and viral infections will be covered. Attendees will leave the session with updated knowledge in dermatopathology.

      • Christine Ko, MD, FAAD: Introduction to What's New In Dermatopathology: COVID19 histopathologic findings

      • Aleodor A. Andea, MD, FAAD: Molecular techniques

      • Joan Guitart: Cutaneous lymphoma

      • Nooshin Ketabchi Brinster, MD, FAAD: Inflammatory diseases

      • John T. Seykora, MD, FAAD: Translational research

      • Travis W. Vandergriff, MD, FAAD: Infections

      • Tammie C. Ferringer, MD, FAAD: Appropriate use criteria

      • Marc Lewin, MD: Soft tissue tumors

    • Cosmetics: Cosmetic Dermatology is an evolving aspect of dermatology and the future of your practice. From the increase in new devices, new technologies and noninvasive aesthetic procedures, we as dermatologists must stay current on the development of technology and use this knowledge to enhance our practice and provide positive outcomes for our patients. This session will provide the dermatologist with what is available now and what the future holds for aesthetics.

      • Susan C. Taylor, MD, FAAD: The Future of Photoprotection for Pigmentary Disorders

      • Diane S. Berson, MD, FAAD: The Future of Acne & Rosacea Skincare

      • Neil S. Sadick, MD, FAAD: The Future of Neuromodulators

    • Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management: This session will review hidradenitis suppurativa (HS) epidemiology and comorbidities, and current concepts of pathogenesis. An evidence-based approach for the use of medical therapies for HS, including topical agents, antibiotics, non-antibiotic systemics and biologics, will be discussed. An approach to HS pain management will also be presented.

      • Haley Naik, MD, FAAD: Introduction

      • John Frew, MBBS: Pathophysiology of hidradenitis suppurativa

      • Joslyn S. Kirby, MD, FAAD: Medical management of HS with biologic therapies

      • Afsaneh Alavi, MD, FAAD: Medical management of HS with non-biologic therapies

      • Amit Garg, MD, FAAD: Epidemiology and comorbidities of hidradenitis suppurativa

      • Steven Daniel Daveluy, MD, FAAD: Laser management of hidradenitis suppurativa

      • Lauren Orenstein, MD, FAAD: Managing pain in HS

    • Skin of Color: This session will provide attendees with insight into skin conditions more commonly seen in patients with skin of color and provide ways to better diagnose and manage these conditions. Disorders of pigmentation will be covered.

      • Amit G. Pandya, MD, FAAD: Unmasking Facial Hyperpigmentation

      • John Harris, MD, PhD, FAAD: What's New In Vitiligo

    • Nail Symposium: This symposium is directed to both general dermatologists and those with a specific interest in nail disorders. The best experts in nail disorders from around the world will present the most up to date data on essential aspects of nail disease.

      • Aurora Maria Alessandrini, MD: Best Uses of Onychoscopy for the Diagnosis of Nail Disorders

      • Jane S. Bellet, MD, FAAD: Systemic Medications for Children with Significant Inflammatory Nail Disease

      • Judith Dominguez-Cherit, MD: Recommendations for Evaluation, and Conservative and Surgical Therapy of Congenital

      • Malalignment of the Great Toenails in Children and Young Adults

      • Nilton Gioia Di Chiacchio, MD, PhD: Evidence and Recommendations for Post-Nail Procedure Analgesia

      • Jorge Ocampo-Garza, MD: Optimizing the Yield of Nail Matrix Sampling and Minimizing Dystrophy

    • Hair Disorders Made Easier: This session will cover the basics of the patient evaluation for hair loss, including diagnostic tips, treatment pearls, ethnic hairstyling, surgical procedures, and clinicopathologic correlation. It is directed at all practitioners who see alopecia patients.

      • Jerry Shapiro, MD, FAAD: Treatment and follow-up of non-scarring alopecia

      • Melissa Piliang, MD, FAAD: Tips on evaluation and diagnosis of scarring alopecia

      • Maryanne Makredes Senna, MD, FAAD: Pearls in the management of scarring alopecia

      • Meena Singh, MD, FAAD: Surgical and alternative treatments for alopecia

    • Systemic Therapies for Dermatologists: A Comprehensive Review and Update: This session provides cutting edge information on a potpourri of topics dermatologists are going to deal with this year. Topics covered include the use of cannabinoids in dermatology;; systemic medications available to treat more aggressive non melanoma skin cancers; diagnosing and managing adverse effects associated with many of these newer medications; and, finally, how to manage pain in the post opioid era.

      • Adam J. Friedman, MD, FAAD: Use of Cannabinoids in Dermatology

      • Anne Lynn S. Chang, MD: Systemic Therapy for Non-melanoma Skin Cancer

      • Jennifer N. Choi, MD, FAAD: Adverse Effects of Newer Systemic Medication

      • Rajiv Nijhawan, MD, FAAD: Management of Pain

    • Psoriasis: This is an overview and update of the current major issues related to psoriasis treatment.

      • Bruce Elliot Strober, MD, PhD, FAAD: Introduction and New Data

      • Joel Gelfand, MD, MSCE, FAAD: Effect of Psoriasis Treatment on Cardiovascular Risk: Reconciling Clinical Trials and Observational Studies

      • Mark Lebwohl, MD, FAAD: Which drug for which patient?

      • Kenneth B. Gordon, MD, FAAD: Debate on the Treatment of "Mild-to-Moderate Psoriasis" with Modern Systemic Therapy

    • Making Teledermatology Work: Dermatologists have been at the forefront of telehealth for the past two decades. In light of current events, even more dermatologists are adopting telehealth services. The purpose of this webinar is to educate dermatologists on the implementation of telehealth in their practices with current regulations from the Centers for Medicare and Medicaid Services (CMS) in mind.

      • Jules Lipoff, MD, FAAD: Introduction

      • George Han, MD, PhD: How to implement teledermatology in your practice

      • Trilok Tejasvi, MD, MBBS: How to use teledermatology in your practice

      • Cynthia Stewart, CPC, COC, CPMA, CPC-I: Coding for teledermatology

      • Cory Simpson, MD, PhD, FAAD: How to choose the right platform for you

    All sessions will be available on-demand beginning Friday, June 12 at 2 p.m. CT.

    Live events, including Q&A with the speakers, will take place Friday, June 12 – Sunday, June 14. All content will be available on-demand through December 31, 2020.

    Late-breaking Research: Clinical Studies/Pediatric

      • The effect of adding combined oral contraceptives or metformin to laser hair removal treatment on the quality of life of polycystic ovarian syndrome patients with hirsutism; a randomized control trial: Dorgham Nevine, MD

      • The Longitudinal Evolution of Skin Microbiome of Children from Birth to 10 Years of Age: Kimberly Capone, PhD

      • Dupilumab Significantly Improves Atopic Dermatitis in Children Aged ≥6 to <12 years: Results From Phase 3 Trial (LIBERTY AD PEDS): Amy S. Paller, MD, FAAD

      • First in Human use of a Novel In Vivo Gene Therapy for the Treatment of Autosomal Recessive Congenital Ichthyosis: Results of a Phase I/II Placebo Controlled Trial: Amy S. Paller, MD, FAAD

      • Secukinumab is Highly Efficacious and Has a Favorable Safety Profile in Pediatric Patients With Moderate-to-Severe Plaque Psoriasis: Professor Adam Reich

      • Intravenous Gentamicin Therapy for Epidermolysis Bullosa: Michelle Hao

      • Creation and Validation of Classification Criteria for Discoid Lupus Erythematosus (DLE): Scott A. Elman, MD

    • Late-breaking Research: Procedural Dermatology

      • Comparing the Efficacy of Combination of Microneedling and 10% Trichloroacetic acid Peels Versus Carbon dioxide Laser Resurfacing in the Treatment of Infraorbital Dark Circles: Banu Farabi

      • The Impact of Synchronous Skin Cancer Identification on Mohs Micrographic Surgery and Reconstruction Plans: Leora Aizman, BS

      • Efficacy and Safety Of High Concentration Trichloro-Acetic Acid (TCA) Chemical Peels In Skin Phototype IV-VI, A South African Melasma Experience: Frans Maruma, MD

      • Assessment of the skin acceptability and efficacy of a cosmetic product in the treatment of hypertrichosis in female patients: Enzo Berardesca, MD

      • The effects of Microfocused Ultrasound in facial rejuvenation: a clinical and experimental study based on immunohistochemical assay: Patricia Meyer, PT, PhD

      • A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection (DAXI) for the Treatment of Dynamic Forehead Lines (FHL) Following Glabellar Line (GL) Injections: Jeremy B. Green MD

      • Improvement in the Appearance of Cellulite Resulting from a Single Treatment with Acoustic Subcision: Interim Findings from a Multi-Center Pivotal Trial: Elizabeth Tanzi, MD

    • Late-breaking Research: Basic Science/Cutaneous Oncology/Pathology

      • Important Measures for Psoriasis beyond PASI 100 – Patient-Reported Symptoms and Molecular Data from Patients Treated with Guselkumab or Adalimumab – A Sub-analysis from VOYAGE 1&2: Andrew Blauvelt, MD, MBA

      • Predicting the potential impact of biologics on cancer survival in patients with psoriasis: a gene expression survival analysis of the Cancer Genome Atlas (TCGA) database: Nikolai Klebanov

      • Impact of Obesity and Body Parameters on Pembrolizumab Toxicity and Efficacy in Patients with Advanced Melanoma: Surya Ravichandran

    • Late-breaking Research: Clinical Trials

      • ARQ-151, Roflumilast Cream, Significantly Improves Chronic Plaque Psoriasis in Phase 2b Study: Mark Lebwohl, MD

      • Risankizumab Versus Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 3 Trial: Richard B. Warren, BSc (Hons), MBChB (Hons), MRCP, PhD

      • Efficacy and safety of bimekizumab in patients with moderate-to-severe plaque psoriasis: results from BE VIVID, a 52-week Phase 3, randomized, double-blinded, ustekinumab- and placebo-controlled study: Kristian Reich, MD, PhD

      • Efficacy and safety of bimekizumab in patients with moderate-to-severe plaque psoriasis: results from BE READY, a 56-week Phase 3, randomized, double-blinded, placebo-controlled study with randomized withdrawal: Kenneth Gordon, MD

      • Pityriasis rubra pilaris treated with ixekizumab; an open-label pilot trial: Teri Greiling, MD, PhD

      • Melanocortin receptor 1 agonist Dersimelagon in erythropoietic protoporphyria: A Multicenter Double-Blind Placebo Controlled Study of 102 Patients: Kirstine Belongie, PhD

      • Efficacy and Safety of Oral Difelikefalin in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus: A Randomised, Placebo-Controlled, Phase 2 Trial: Gil Yosipovitch, MD

      • Lebrikizumab, a High-Affinity IL-13 Inhibitor, Demonstrates Rapid and Clinically Meaningful Improvements in Quality of Life Measures in a Phase 2b Trial of Moderate-to-Severe Atopic Dermatitis Patients: Emma Guttman-Yassky, MD

      • Efficacy and safety of tralokinumab monotherapy in adult patients with moderate-to-severe atopic dermatitis: Results from two 52-week Phase 3 trials (ECZTRA 1 and ECZTRA 2): Eric L. Simpson, MD, MCR

      • Efficacy and safety of tralokinumab with concomitant topical corticosteroid in adult patients with moderate-to-severe atopic dermatitis: Results from the 32-week Phase 3 ECZTRA 3 trial: Jonathan Silverberg

      • Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE MONO-2 Study: Melinda Gooderham

      • BELIEVE-PV Phase II Part B Study: Extended Treatment With PRN1008 Improves Outcomes For Patients With Pemphigus: Dedee F. Murrell, MD

      • A Phase 3, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 5% in Japanese Patients with Primary Axillary Hyperhidrosis: Tomoko Fujimoto, MD, PhD

      • Assessment of efficacy and safety of topical administration of 1% glycopyrronium bromide (GPB) in patients with primary axillary hyperhidrosis: Christoph Abels, MD, PhD

    • Immediate-Past President’s Address: George J. Hruza, MD, MBA, FAAD

    • DermTales: Susan Boiko, MD, FAAD - Flowers Every Month

    • President Address: Bruce H. Thiers, MD, FAAD

    • Keynote speaker: Larry Sabato - Crystal Ball

    • DermTales: Mary Maloney, MD, FAAD - Jane Goes to the Dentist

    Exhibit Hall – connect one on one with industry in our exhibit halls.

    Networking – engage in discussions with your colleagues in the following designated lounges: Academic, Private practice, and Residents. Share your experience and follow along on social with #AADVMX2020.

    Member Center – explore AAD resources such as JAAD and AAD preferred providers, talk to AAD staff in the Resource Center, and show recognition to the Stars of the Academy & Individual Donors.

    Corporate Partners – AAD VMX is made possible through the generous support of our corporate partners. Stop by our recognition hall to meet our partners.

    Residents registered for AAD VMX will be able to access sessions to help prepare for the boards, connect with other residents in a networking lounge, participate in a residents’ challenge, and search opportunities on AAD Career Compass’s job board.

    All sessions will be available on-demand beginning Friday, June 12 at 2 p.m. CT.

    Live events, including Q&A with the speakers, will take place Friday, June 12 – Sunday, June 14. All content will be available on-demand through December 31, 2020.

    Resident sessions

    • Basic Self-assessment of Dermatopathology Slide Review and Discussion: For this session, participants will have reviewed 60 digitally scanned slides representing common and uncommon skin diseases, both neoplastic and inflammatory. Diagnoses (and differential diagnoses) will be reviewed and discussed by faculty.

      • Travis W. Vandergriff, MD, FAAD

      • Tammie C. Ferringer, MD, FAAD

      • Christine Ko, MD, FAAD

      • Yevgeniya Byekova Rainwater, MD, FAAD

      • Jeffrey P. North, MD, FAAD

      • Olayemi Sokumbi, MD, FAAD

      • Lori Lowe, MD, FAAD

      • Kiran Motaparthi, MD, FAAD

    • Conquer the Boards: An Experiential Review: This Certification Exam Prep Course is a hands-on experience where attendees take a simulated, shortened version of the American Board of Dermatology certification exam.

      • Allen Strickler, MD, PhD, MPH, FAAD

      • Jeffrey P. North, MD, FAAD

      • Allen Strickler, MD, PhD, MPH, FAAD

      • Jeffrey P. North, MD, FAAD

      • Oluwakemi Onajin, MD, FAAD

      • Bethanee Schlosser, MD, PhD, FAAD

      • Matthew Vesely, MD, PhD, FAAD

      • Esteban Fernandez Faith, MD, FAAD

      • Jonathan Scott Leventhal, MD, FAAD

      • Jennifer Lucas, MD, FAAD

    Residents’ Challenge – test your knowledge through 20 quiz questions and see how you stack up against your peers on the leaderboard.

    2020 Abstract books:

    Congratulations to the winners of the VMX badge raffle!

    First Place:
    Wendi Wohltmann, MD, FAAD

    Second Place:
    Lori Astalos, MD, MS, FAAD
    Mona Zaher, MD, FAAD

    Third Place:
    Najd Manie